Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate N-of-1 series in Smith-Magenis syndrome with ADHD
NL-OMON52697Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) and Smith-Magenis syndrome (SMS) comparing Methylphenidate period with Placebo period (2 arms). Primary endpoint: ADHD symptoms. Started Apr 2022; status: active, not recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)Smith-Magenis syndrome (SMS)
Beyond the preview
Go deeper on NL-OMON52697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52697.